Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia.
29 patients with primary hypercholesterolemia were treated for 8 weeks each with either bezafibrate (200 mg t.i.d.) or gemfibrozil (600 mg b.i.d.) in a randomized cross-over trial. Compared to placebo bezafibrate was significantly more effective on low density lipoprotein (LDL)-cholesterol (-28% versus -18%) and the LDL/high density lipoprotein (HDL) ratio (-34% versus -24%) by exploratory statistics. There was also a trend for a more marked reduction of bezafibrate on total cholesterol and apoliproprotein B as well as more pronounced increase in HDL-cholesterol and apolipoprotein A-I. The triglyceride reduction tended to be more extensive with gemfibrozil. Complicance to both drugs was good. No side-effects were observed. The results are considered important with respect to the potential of bezafibrate in reducing the risk of cardiovascular disease.
Weisweiler
P
P
iphar Institut für Klinische Pharmakologie GmbH, Munich, Fed. Rep. of Germany.
D000328:Adult; D000368:Aged; D001629:Bezafibrate / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged
D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D015248:Gemfibrozil; D001629:Bezafibrate